{'fraction_non_alphanumeric': 0.024163568773234202, 'fraction_numerical': 0.011152416356877323, 'mean_word_length': 6.18, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ALMOST NORMAL COGNITIVE FUNCTION IN PATIENTS DURING THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITHOUT CRANIAL IRRADIATION ACCORDING TO ALL-BFM 95 AND COALL 06-97 PROTOCOLS: Results of an Austrian–German Multicenter Longitudinal Study and Implications for Follow-Up

In a multicenter study the authors prospectively investigated neurocognitive function in childhood ALL patients. Sixty-six patients (mean age at diagnosis 7.9 ± 3.6 years, 34 female), treated with repeated intrathecal and systemical methotrexate administrations without cranial irradiation, underwent psychometric testing for intelligence, concentration, and visual-motor integration postdiagnosis and after reinduction therapy. Although there was a statistically significant decline of intellectual function after reinduction therapy for younger patients and girls (IQ scores still within normative data range), there were no differences in visual-motor performance and concentration over the time of induction therapy. Thus, neurocognitive examination should focus on younger ALL patients and girls.